BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1411 related articles for article (PubMed ID: 8842346)

  • 1. General pharmacology of recombinant human basic fibroblast growth factor.
    Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T
    Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
    Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS
    Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
    Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General pharmacological properties of the main metabolite of flosequinan.
    Fujita S; Ikezono K; Umezato M; Hosoki E; Toba Y; Ishikawa M; Kusunoki A; Shintani S
    Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General pharmacological properties of the new vasodilator flosequinan.
    Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
    Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
    Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H
    Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
    Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
    Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General pharmacology of the new quinolone antibacterial agent levofloxacin.
    Takasuna K; Kasai Y; Usui C; Takahashi M; Hirohashi M; Tamura K; Takayama S
    Arzneimittelforschung; 1992 Mar; 43(3A):408-18. PubMed ID: 1622443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General pharmacology of beraprost sodium. 2nd communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects.
    Murata T; Murai T; Kanai T; Ogaki Y; Sanai K; Kanda H; Sato S; Kajikawa N; Umetsu T; Matsuura H
    Arzneimittelforschung; 1989 Aug; 39(8):867-76. PubMed ID: 2510743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological studies on timiperone, a new neuroleptic drug Part II: General pharmacological properties.
    Yamasaki T; Kojima H; Tanaka M; Aibara S; Hirohashi M; Kasai Y; Tsubokawa M; Watanabe K; Akashi A
    Arzneimittelforschung; 1981; 31(4):707-15. PubMed ID: 6113834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General pharmacological profiles of the new beta-adrenoceptor antagonist carvedilol.
    Hirohashi M; Takasuna K; Tamura K; Yamaguchi K; Maekawa K; Yamada S; Iwasaki S; Yoshida M; Nomura M; Taguchi K
    Arzneimittelforschung; 1990 Jul; 40(7):735-46. PubMed ID: 1977393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. General pharmacological profile of the new anti-ulcer drug 3-[[[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl]methyl]-amino-N -methylbenzamide.
    Hirohashi M; Takasuna K; Kasai Y; Usui C; Tamura K; Kojima H
    Arzneimittelforschung; 1993 May; 43(5):569-77. PubMed ID: 8329002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. General pharmacological properties of muroctasin.
    Kojima H; Hirohashi M; Kasai Y; Takasuna K; Fukumoto C; Akashi A
    Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on cardiovascular, visceral and renal functions and on hemodynamics.
    Yamamoto S; Takemori E; Hasegawa Y; Kuroda K; Nakao K; Inukai T; Sakonjyo H; Nishimura T; Nishimori T
    Arzneimittelforschung; 1991 Sep; 41(9):913-23. PubMed ID: 1796919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
    Kito G; Morimoto S; Shiomi M
    Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. General pharmacology of the new non-xanthine adenosine A1 receptor antagonist (+)-(R)-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2- piperidine ethanol.
    Terai T; Kusunoki T; Kita Y; Yoshida K; Akahane A; Shiokawa Y; Kohno Y; Horiai H; Mori J; Mine Y; Kohsaka M
    Arzneimittelforschung; 1996 Feb; 46(2):185-91. PubMed ID: 8720311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. General pharmacology of recombinant human tumor necrosis factor. 1st communication: effects on cardiovascular, gastrointestinal, renal and blood functions.
    Nakatsuji K; Kii Y; Fujitani B; Ito T
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):218-25. PubMed ID: 2334464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 2nd communication: effects on somatic nervous system and on autonomic nervous system and smooth muscle.
    Arisawa H; Fukui K; Fujise N; Masunaga H
    Arzneimittelforschung; 2002; 52(2):81-8. PubMed ID: 11878203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [General pharmacology of T-3761, a new oral quinolone antibacterial agent (2). Effect on the respiratory and cardiovascular systems, autonomic nervous system and other functions].
    Furuhata K; Hiraiwa T; Terashima N; Arai H; Ono S; Hashiba K; Maekawa M; Kitamura K; Nakada Y; Mori Y
    Jpn J Antibiot; 1995 May; 48(5):706-32. PubMed ID: 7637205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.